Dr. Mike Cusnir, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 32
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 464
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME87084 -
Specialist
FL license ME87084
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mount Sinai Medical Center of Florida, Inc Miami Beach, FL
- Doctors Hospital Coral Gables, FL
Medical groups
- Physician Practices of Msmc LLC (181 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 464
- Services billed
- 1,550
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 1,092 | 385 |
| Established patient office or other outpatient visit, 30-39 minutes | 261 | 127 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 83 | 47 |
| New patient office or other outpatient visit, 45-59 minutes | 42 | 42 |
| New patient office or other outpatient visit, 30-44 minutes | 24 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Miami Beach, FL | 139 |
| Prednisone Other prescribers in Miami Beach, FL | 122 |
| Abiraterone Acetate | 100 |
| Oxycodone Hcl Other prescribers in Miami Beach, FL | 90 |
| Tramadol Hcl Other prescribers in Miami Beach, FL | 87 |
| Xtandi (enzalutamide) | 83 |
| Revlimid (lenalidomide) | 72 |
| Ondansetron Hcl Other prescribers in Miami Beach, FL | 57 |
| Eliquis (apixaban) Other prescribers in Miami Beach, FL | 55 |
| Erleada (apalutamide) | 54 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 59 companies reported 360 payments worth $16,779 in total to this clinician.
| Jazz Pharmaceuticals Inc. | $5,512 |
|---|---|
| Novartis Pharmaceuticals Corporation | $3,156 |
| Janssen Biotech, Inc. | $684 |
| Pfizer Inc. | $603 |
| Celgene Corporation | $584 |
| Merck Sharp & Dohme LLC | $400 |
| Incyte Corporation | $352 |
| Daiichi Sankyo Inc. | $317 |
| Food and Beverage | $8,572 |
|---|---|
| Consulting Fee | $7,891 |
| Education | $317 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. Dec 15, 2025 | Consulting Fee ZIIHERA · HEMATOLOGY/ONCOLOGY | $5,441 |
| Novartis Pharmaceuticals Corporation May 30, 2025 | Consulting Fee | $2,450 |
| Incyte Corporation May 23, 2025 | Education | $99.95 |
| Seagen Inc. May 20, 2025 | Education in-kind | $91.99 |
| Astellas Pharma US Inc Sep 19, 2025 | Education in-kind | $75.00 |
| Merck Sharp & Dohme LLC Jun 4, 2025 | Education KEYTRUDA QLEX · ONCOLOGY · in-kind | $25.70 |
| Janssen Pharmaceuticals, Inc Jul 30, 2025 | Education in-kind | $15.99 |
| Janssen Pharmaceuticals, Inc Aug 15, 2025 | Education in-kind | $8.24 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 12 companies. The companies reported $554,619 in research payments for these studies, mostly to the institutions running them.
- An openlabel randomized phase 3 study of tucatinib in combination with trastuzumab and MFOLFOX6 versus MFOLFOX6 given with or without either cetuximab or bevacizumab as firstline treatment for subjects with HER2 metas…
Pfizer Inc. - A Phase 2 Study of Futibatinib in Combination With PD-1 Antibody-based Standard of Care Therapy in Patients With Solid Tumors.
Taiho Oncology, Inc. - A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wildtype Recurrent Metastatic Colorectal Cancer Who Have Received Prior Ch…
Janssen Research & Development, LLC - NCT02360579
Iovance Biotherapeutics, Inc. - An openlabel multicenter randomized phase 3 study of firstline encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety leadin of encorafenib and cetuximab plus chemotherap…
Pfizer Inc. - Study name not reported
Rigel Pharmaceuticals, Inc. - A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1042 in Subjects With Malignant Solid Tumors.
Genmab U.S., Inc. - A phase 2 randomized openlabel study of encorafenib and cetuximab plus pembrolizumab versus pembrolizumab alone in participants with previously untreated braf V600EMUTANT msi hdmmr metastatic colorectal cancer
Pfizer Inc. - A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
Exelixis Inc. - EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma
Novocure Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.